{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:52:52Z","timestamp":1778010772874,"version":"3.51.4"},"reference-count":20,"publisher":"Microbiology Society","issue":"10","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"abstract":"<jats:p>In cystic fibrosis (CF) patients, Gram-negative <jats:italic>\n                     <jats:named-content content-type=\"species\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.1620\" xlink:type=\"simple\">Burkholderia cepacia<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> complex (Bcc) infections are associated with recurrent pulmonary exacerbations. Bcc organisms are innately resistant to many antibiotics, and infection with <jats:italic>\n                     <jats:named-content content-type=\"species\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.1627\" xlink:type=\"simple\">B. cenocepacia<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> is a contraindication to lung transplantation. We report a CF patient with severe lung disease, colonized with Bcc, with a history of around nine exacerbations per year for over 10\u2009years, for whom antibiotic regimens (including targeted and broad-spectrum antibiotics) had not cleared infection or extended the interval between exacerbations. After receiving a 2\u2009week cefiderocol-containing regimen, the patient remained stable for more than 5\u2009months without the need for additional antibiotics or hospital admissions for respiratory exacerbations.<\/jats:p>","DOI":"10.1099\/acmi.0.000413","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T16:17:03Z","timestamp":1665159423000},"source":"Crossref","is-referenced-by-count":8,"title":["Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis: a case report"],"prefix":"10.1099","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-0993","authenticated-orcid":false,"given":"Clemency","family":"Nye","sequence":"first","affiliation":[{"name":"Public Health Wales Microbiology Cardiff, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[{"name":"All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Cardiff CF64 2XX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Dhillon","sequence":"additional","affiliation":[{"name":"Public Health Wales Microbiology Cardiff, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009529.pub4"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-020-0258-5"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009529.pub3"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2011.00018"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009876.pub4"},{"key":"R6","article-title":"UK cystic fibrosis registry annual data report 2019","author":"Trust","year":"2019"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.017210"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.01.002"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03237.x"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201408-395OC"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25552"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0602"},{"key":"R13","article-title":"Cefiderocol. Cefidericol summary of product characteristics"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"R15","article-title":"Shionogi data on file (cefiderocol compassionate use programme-unpublished)","year":"2022"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.798"},{"key":"R17","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections","author":"Warner","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24945"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13716"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00685-20"}],"container-title":["Access Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/acmi\/10.1099\/acmi.0.000413?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T19:34:30Z","timestamp":1702582470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/acmi\/10.1099\/acmi.0.000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1099\/acmi.0.000413","relation":{},"ISSN":["2516-8290"],"issn-type":[{"value":"2516-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}